Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | CTSL | P07711 | 2/20 | 0.59 |
| ▸ | CTSS | P25774 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 3/20 | 0.57 |
| ▸ | IL1RN | P18510 | 2/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.55 |
| ▸ | ECE1 | P42892 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16463539 | 1.00 | TACR1 (0.60) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL4842487 | 0.88 | TACR1 (0.56) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL30406730 | 0.88 | TACR1 (0.66) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL23065018 | 0.85 | ACE (0.60) | ACEIL1RNERAP2ECE1 | |
| SCHEMBL4068546 | 0.85 | CTSL (0.56) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL25453628 | 0.84 | TACR1 (0.58) | TACR1CTSLCTSSCTSKMAPT | |
| SCHEMBL8905663 | 0.84 | ECE1 (0.74) | ACEIL1RNERAP2ECE1 | |
| SCHEMBL23875110 | 0.84 | ECE1 (0.64) | ACEECE1 | |
| SCHEMBL9235805 | 0.84 | ACE (0.78) | ACEECE1 | |
| SCHEMBL1228369 | 0.84 | ACE (0.78) | ACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
| EP-2906581-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| CN-104837858-A | Ketoamide immunoproteasome inhibitors | HOFFMANN LA ROCHE | 2015-08-12 | — | — | CN | disclosed |
| WO-2014056748-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | PSMB7, PSMB5, PSMC2 | TACR1 3927/4885CTSL 554/4885CTSS 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.